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Abstract
Background: Secondary peritonitis is an advanced form of complicated intra-abdominal infection (cIAI) re-
quiring hospitalization, surgical source control, and empiric antibiotic therapy against causative aerobic and
anaerobic bacteria.
Methods: This pooled analysis of four prospective, active-controlled randomized clinical trials compared the
efficacy and safety of moxifloxacin with that of comparator antibiotics in patients with confirmed secondary
peritonitis. The primary efficacy endpoint was clinical success rate at test-of-cure (TOC) between day 10 and 45
post-therapy in the per-protocol (PP) population. Safety and clinical efficacy were assessed also in the intent-to-
treat population (ITT). Bacteriological success was assessed at TOC in the microbiologically-valid population
as a secondary efficacy endpoint.
Results: Overall clinical success rates at TOC were 85.3% (431 of 505 patients) in the moxifloxacin and 88.4%
(459 of 519 patients) in the comparator treatment groups (PP population, point estimate for the difference in
success rates: - 3.0%; 95% CI - 7.06%, 1.05%), respectively. Similar clinical success rates between moxi-
floxacin and comparators were observed by anatomical site of infection, and ranged from 80.6% to 100% for
moxifloxacin and from 71.4% to 96.6% for comparators, respectively. Bacteriologic success rates were similar
with moxifloxacin (82.4%) and comparators (86.8%), respectively. The proportion of patients experiencing any
treatment-emergent adverse events was slightly higher with moxifloxacin (67.3%) versus comparators (59.8%).
Rates of drug-related adverse events (20.9% versus 20.0%) and deaths (4.3% versus 3.4%) were similar in
moxifloxacin and comparator groups; none of the deaths were drug-related.
Conclusions: The data suggests that once-daily IV (or IV/PO) moxifloxacin has a comparable efficacy and
safety profile to antibiotic regimens approved previously in the subgroup of patients with secondary peritonitis
of mild-to-moderate severity.
Secondary peritonitis can arise from perforation orpenetrating injury of the gastrointestinal tract as well as
from ischemic necrosis [1]. Complicated intra-abdominal
infections (cIAIs) require hospitalization, adequate surgery,
antibiotic therapy, and continuous supportive care and
monitoring [2,3]. If these interventions are delayed or inad-
equate, secondary peritonitis can spread rapidly throughout
the abdominal cavity; up to 40% of patients with secondary
peritonitis may progress to sepsis or septic shock with high
mortality rates approaching 30–40% [1].
The bacteriologic etiology of secondary peritonitis is fre-
quently polymicrobial due to concurrent infection with gram-
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positive and gram-negative aerobic and anaerobic pathogens
[1,3–7]. Escherichia coli is usually the major aerobic isolate,
although Bacteroides fragilis and other Bacteroides spp. are
also anaerobes isolated frequently [5,6].
Current guidelines recommend empirical broad-
spectrum antibiotic therapy as exact information on the re-
sponsible bacterial species and susceptibility results are rarely
known when the treatment is initiated. Adequate source
control and prompt, appropriate empiric treatment is essential
to improve outcome [3,4,8] and to reduce mortality [9].
Fluoroquinolones, which are broad-spectrum antibiotics with
favorable efficacy and safety profiles for the management of
mild-to-moderate cIAIs either asmonotherapy (moxifloxacin)
or in combination therapy (levofloxacin, ciprofloxacin), are
recommended in the latest Surgical Infection Society (SIS)/
Infection Infectious Diseases Society of America (IDSA)
guidelines for the treatment of mild-to-moderate infections
[3,4]. Moxifloxacin has a favorable pharmacokinetic/phar-
macodynamic (PK/PD) profile with an excellent penetration
into gastrointestinal tissues, including abdominal abscesses
[10] and peritoneal exudates in patients with peritonitis [11]. It
is available in intravenous (IV) and oral formulations for
once-daily administration [12].
Complicated IAIs encompass a wide spectrum of diseases
in terms of peritoneal expansion, systemic response, surgical
approach, andmortality rate. Secondary peritonitis represents
the most severe forms of cIAIs (as opposed to localized or
uncomplicated disease) due to its extent, inoculum size, and
systemic response, either acquired in the community or as-
sociated with healthcare institutions.
On the basis of pooled data from the four Phase III random-
ized, active-controlled, prospective clinical trials [13–16]
comparingtheefficacyandsafetyofmoxifloxacinmonotherapy
withthatofcomparatorregimens inmild-to-moderatecIAIs,we
undertook a retrospective analysis of the efficacy and safety of
moxifloxacin in this subgroup of patients with secondary peri-
tonitis, reflecting an advanced form of peritonitis.
Patients and Methods
Design of studies used in the analysis
Of the four randomized controlled trials (conducted be-
tween 2000 and 2009), three were double-blind [13,15–16]
and one study was open-label [14]. All studies were designed
to demonstrate the non-inferiority of moxifloxacin to com-
parator antibiotic regimens and used a non-inferiority margin
of either 10% [13–14,16] or 15% [15]. All four studies were
performed in accordance with the Declaration of Helsinki,
the rules of International Conference on Harmonization
(ICH) Good Clinical Practice and relevant national guide-
lines. Independent Ethics Committees approved the respec-
tive study protocols and written consent prior to enrollment
from all patients in each study was obtained. The main re-
gions enrolling patients in these studies were the United
States [13], Asia [15], and Europe [14,16]. The clinical di-
agnoses were described in detail in the clinical study protocol
and approved by regulatory authorities prior to the initiation
of the studies in each individual study. They were collected
on the case report form (CRF) in the four studies, and stored
in the respective individual trial database. Finally, they were
transferred to the pooled database of the studies. The CRF
was not standardized across the four studies that would have
captured specific cIAI diagnosis. If multiple diagnoses were
documented in the CRF for the same patient, the primary
diagnosis and the site of infection were determined and
evaluated for validity of secondary peritonitis. For the pur-
pose of documentation, a statistical analysis plan was pre-
pared prior to performing the pooled subgroup analysis.
Inclusion criteria
Eligible patients were adults (‡ 18 y) with a primary diag-
nosis of cIAI that was supported by radiologic evidence of
gastrointestinal tract perforation and required surgical inter-
vention by laparotomy or laparoscopy [13–16] or percutaneous
aspiration [13–15] for sourcecontrol in addition to IVantibiotic
therapy. Patients also had evidence of gross peritoneal in-
flammation with purulent exudates into the peritoneal cavity.
Diagnosis could also be suspected in patients with radiological
evidence of gastrointestinal perforation, and the presence of at
least one abdominal cavity symptom lasting ‡ 24 h, together
with evidence of at least one of abdominal tenderness, absent or
diminished bowel sounds, or abdominal wall rigidity and at
least two systemic signs of infection that included elevated
body temperature (> 38.3OC rectal or tympanic membrane,
>37.8OC oral, or >37.3OC axillary), heart rate of > 90 beats/
min, respiratory rate of > 20breaths/min, and awhite blood cell
count of > 12,000 cells/mm3 or < 4,000 cells/mm3. It had to be
confirmed by surgical findings within 24 h of enrollment [13–
16]. Severity of the disease was described by the Acute Phy-
siology and Chronic Health Evaluation (APACHE) II score in
the current analysis.
Exclusion criteria
Main exclusion criteria were: Spontaneous bacterial peri-
tonitis, conditions not requiring antibiotic therapy for a
minimum of three days (e.g., non-complicated acute appen-
dicitis, acute cholecystitis with infection confined to the
gallbladder, transmural necrosis of the intestine due to acute
embolic, thrombotic, or obstructive occlusions); the presence
of known prolongation of the electrocardiogram (ECG) QT
interval, uncorrected hypokalemia, concomitant antiar-
rhythmic drugs; severe infection requiring high-dose vaso-
pressor drugs; acute kidney injury; and contraindications to
study drugs (e.g., pregnancy, breastfeeding, or hypersensi-
tivity) [13–16].
Antibiotic regimens
In all four studies, patients were randomized to receive IV
moxifloxacin 400mg (Avelox, GP) once daily (QD) for up
to 14 d [13–16], with the option to switch to per os (PO)
moxifloxacin [12] 400mg after a minimum of three days in
two studies [13–14]. The comparator treatments included the
following antibiotics: i, Piperacillin-tazobactam [17], 3.0g/
0.375g IV, four times daily (QID), followed by amoxicillin/
clavulanic acid [18], 800mg/114mg PO, twice daily (BID)
[13]; ii, ceftriaxone [19], 2.0g QID plus metronidazole [20],
500mg IV, three times daily (TID), followed by amoxicillin/
clavulanic acid [18], 500mg/125mg PO, TID [14]; iii, cef-
triaxone [19], 2.0g QD plus metronidazole [20], 500mg IV,
BID [15]; and iv ertapenem [21], 1.0 g IV, QID [16], re-
spectively. The minimum length of antibiotic therapy was
either five days in studies conducted by Malangoni et al. [13]
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and DeWaele et al. [16] or three days in studies conducted by
Weiss et al. [14] and Solomkin et al. [15].
Outcome parameters
The primary efficacy endpoint in all four studies was clin-
ical success at test-of-cure (TOC) that occurred between day
10 and 45 after antibiotic therapy in the per-protocol (PP)
population (according to individual studies: 11–45 d [13]; 14–
37 d [14]; 10–14 d [15]; and 21–28 d [16]. Clinical success was
defined as continued resolution or improvement of clinical
signs and symptoms related to the infection not requiring any
antibiotic therapy, and without the occurrence of any surgical
infection requiring a systemic antibiotic treatment at TOC.
Secondary efficacy outcome parameters were clinical success
rate at TOC by anatomic site of infection, bacteriologic suc-
cess (eradication plus presumed eradication) rate at TOC by
anatomical site of infection (for overall and by bacteria type)
and bacteriologic success rate for main organisms at TOC by
the anatomic site of the infection [13–16].
Statistical analyses
Clinical efficacy assessments were based primarily on the
PP population, which included all patients who met study
specific criteria that were common to all four studies. These
criteria included: 1, cIAI requiring surgery and supportive
management; 2, no other systemic antimicrobial agent ad-
ministered concomitantly with the study drug unless the
subject was a treatment failure; 3, documented compliance
with ‡ 80% of the study medication administered; 4, no
protocol violations influencing the treatment efficacy; and 5,
successful completion of an assessment at the test-of-cure
(TOC) visit. Safety parameters were assessed in the intent-to-
treat (ITT) population that included all randomized patients
who had received at least one dose of study medication and
had at least one observation after study drug intake. This
pooled analysis also compared the clinical efficacy of mox-
ifloxacin treatment with that of pooled comparator treatment
in the ITT population. Secondary efficacy assessments in-
cluded bacteriologic outcome parameters in the microbio-
logically-valid (MBV) population that included all patients
who met the inclusion criteria in the PP population and had a
causative organism at baseline as well as a bacteriological
evaluation at the TOC visit. For the primary efficacy analysis,
differences in clinical success rates for moxifloxacin versus
pooled active comparator treatment in the PP population
were calculated using a Mantel-Haenszel type analysis
stratified by study, with 95% confidence intervals (CIs) for
the difference in success rates computed according to Roth-
man et al. [22]. To assess possible heterogeneity of clinical
success rates across the four studies, the Q test was applied
where significance at the 10% level indicated statistical het-
erogeneity [23]. Forest plots were created to visualize the
variability of the difference in success rates across trials. All
analyses were exploratory in nature; confirmatory statistics
were not carried out.
Results
Patients’ demographic characteristics
Across the four studies, 1,229 patients had a confirmed
diagnosis of secondary peritonitis in the ITT population, of
whom 1,024 met the inclusion criteria in the PP population. A
large proportion of patients (52.2%, 642 of 1,229 patients)
included in these pooled analyses originated from the PRO-
MISE study [16]. Baseline demographic and disease char-
acteristics were similar for moxifloxacin-treated patients and
those in the comparator arms in both the ITT and PP popu-
lations (Table 1). The whole pooled study population was
predominantly under 50 y of age, approximately 71% of the
patients had a comorbid illness and 37% of the patients were
treated previously with a different antibiotic agent prior to
study drugs. Most patients had community-acquired ( > 95%)
cIAIs of polymicrobial etiology ( > 60%) that were ofmild-to-
moderate severity on the basis of APACHE II scores
(mean –SD, 7.0– 5.0). Approximately 3% of the patients had
bacteremia. Consistent with a diagnosis of secondary peri-
tonitis, patients showed signs of infection such as fever
(median 38.5C), raised white blood cell count, and high
concentrations of C-reactive protein (Table 1).
Efficacy analyses
Clinical efficacy. The primary endpoint, namely that
moxifloxacin was non-inferior with regards to clinical effi-
cacy versus comparator regimens in the cIAI patient popu-
lations as defined in the individual study protocols, was
achieved in all four clinical studies. In the subgroup of pa-
tients with secondary peritonitis, the clinical success rates at
TOC were 85.3% and 88.4% in the moxifloxacin and com-
parator treatment arms of the PP population, respectively,
(point estimate for the difference in success rates: - 3.01%;
95% CI: - 7.06%, 1.05%) (Table 2, Fig. 1). Corresponding
clinical success rates for the ITT population were 73.7%
and 77.7%, respectively (point estimate - 3.96%; 95% CI:
- 8.54%, 0.61%) (Table 2, Fig. 1). The point estimates for the
difference in clinical success rates in the PP population
ranged from - 18.33% [15] to 1.4% [13], but the test of
heterogeneity showed no significance at the 10% level indi-
cating that the point estimates were consistent across the four
studies included in the analysis (Table 2).
When analyzed by anatomical site of infection across the
studies, moxifloxacin monotherapy achieved similar clinical
success rates to comparators in infections localized in the
gallbladder and biliary tract, stomach or duodenum, appen-
dix, large bowel, small bowel, or in other locations (Table 3).
Bacteriologic efficacy. Escherichia coli and Bacteroides
fragilis were the pathogens isolated most commonly from
patients with secondary peritonitis which is in accordance
with previous studies [5,24]. This pooled analysis revealed
that in the MBV population, E. coli was isolated in 67.6%
(269/398) of moxifloxacin- and 68.5% (270/394) of com-
parator-treated patients across the four clinical trials. The
second species cultured most frequently was B. fragilis in
26.9% (107/398) of moxifloxacin- and 28.9% (114/394) of
comparator-treated patients. Other Bacteroides species such
as B. thetaiotaomicron (14.1% vs. 14.2%), B. distasonis
(4.5% vs. 4.1%), B. ovatus (6.0% vs. 3.8%), B. uniformis
(4.3% vs. 5.8%), and B. vulgatus (5.0% vs. 2.3%) were iso-
lated less frequently. P. aeruginosa was isolated from 13.1%
(52/398) and 9.1% (36/394) of moxifloxacin- and compara-
tor-treated patients, respectively. Enterococcus avium (6.3%
vs. 5.8%), E. faecalis (9.0% vs. 10.7%), E. faecium (5.8% vs.
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5.1%) were also isolated but in lower frequency from patients
with secondary peritonitis.
The majority of infections in patients with secondary
peritonitis were due to either aerobic bacteria (40.2% and
46.0% of moxifloxacin- and comparator-treated patients,
respectively) or to a mix of aerobic and anaerobic bacte-
ria (56.8% and 51.8% of moxifloxacin- and comparator-
treated patients, respectively). In the MBV population, 11
moxifloxacin- and eight comparator-treated patients had only
anaerobic bacteria isolated.
Consistent with the clinical success rates, pooled bacteri-
ologic success rates suggested that moxifloxacin was as ef-
fective as comparators (82.4% vs. 86.8%, Table 4).
Treatment of patients with only anaerobic bacteria resulted in
lower but comparable eradication rates (Table 4). Moxi-
floxacin was as effective as comparator antibiotics against
E. coli (84.4% vs. 87.4%, respectively) and B. fragilis (84.1%
vs. 88.6%, respectively) (Table 5).
Safety
Adverse events (AEs) occurred in 67.3% and 59.8% of the
moxifloxacin and comparator treatment regimens in the ITT
population, respectively (Table 6). The most common adverse
events in moxifloxacin-treated patients (MXF) versus com-
parator-treated patients were nausea and diarrhea. Further-
more, as a consequence of open abdominal surgery, surgical
infections (or these could be considered as surgical site in-
fections) occurred in 10.7% (65/609) and 8.2% (51/620) of
moxifloxacin- and comparator-treated patients, respectively.
Approximately 20% of patients had drug-related AEs in each
group (MXF: 20.9% vs. COMP: 20.0%), of which 19 (3.1%)
and six (1.0%) experienced serious drug-related AEs in the
moxifloxacin and comparator treatment arms, respectively.
The difference in the frequency of serious drug-related AEs
between moxifloxacin and comparators was driven mainly by
gastrointestinal disorders, surgical infections, asymptomatic
prolongation of the QT interval on the ECG, and increased
liver enzymes. One patient (0.16%) in the MXF group and
three patients (0.5%) in the COMP group had Clostridium
difficile colitis as adverse event; and there was one patient with
clostridial infection in the COMP group as reported adverse
event in this subset of patients. The C. difficile colitis case was
related to the study drug in the MXF-treated patient; however,
this was not a serious AE. In the COMP group two cases of C.
difficile colitis were serious AEs and these were both related to
the study drug. Treatment was discontinued prematurely in
5.1% ofMXF and in 4.0%of those in the comparator treatment
arm (Table 6). Deaths, none of which were attributed to study
medication, occurred with a similar frequency in both
Table 1. Demographics and Baseline Characteristics of Patients with Secondary Peritonitis
in the Pooled Analysis of cIAIs
PP population ITT population
Characteristic
All patients
(N = 1,024)
Moxifloxacin
(N = 505)
Comparators
(N = 519)
All patients
(N = 1,229)
Moxifloxacin
(N = 609)
Comparators
(N = 620)
Gender, male, n (%) 673 ( 65.7) 330 ( 65.3) 343 (66.1) 807 (65.7) 396 (65.0) 411 (66.3)
Mean age – SD, y 46.7 – 18.4 46.3 – 18.3 47.0 – 18.6 47.6 – 18.7 47.6 – 18.7 47.7 – 18.6
Age ‡ 65 y, n (%) 208 ( 20.3) 94 ( 18.6) 114 (22.0) 269 (21.9) 128 (21.0) 141 (22.7)
Mean BMI, kg/m2 (SD) 25.7 – 4.9 25.9 – 4.8 25.5 – 5.0 25.9 – 5.1 26.2 – 5.1 25.7 – 5.1
Coexisting illnesses, n (%) 700 ( 68.4) 353 ( 69.9) 347 (66.9) 872 (71.0) 443 (72.7) 429 (69.2)
Origin of infection,
community-acquired, n (%)
983 ( 96.0) 486 ( 96.2) 497 (95.8) 1,174 (95.5) 584 (95.9) 590 (95.2)
Mean duration of symptoms,
d (SD)
4.2 – 2.5 4.2 – 2.7 4.1 – 2.3 4.2 – 2.6 4.3 – 2.6 4.2 – 2.5
> 2 d, n (%) 881 ( 86.0) 433 (85.7) 448 (86.3) 1,057 (86.0) 521 (85.6) 536 (86.5)
Previous antibiotic therapy*,
n (%)
348 ( 34.0) 167 (33.1) 181 (34.9) 463 (37.7) 223 (36.6) 240 (38.7)
Mean core temperature,
C (SD)
38.5 – 0.92 38.5 – 0.90 38.5 – 0.94 38.5 – 0.93 38.5 – 0.92 38.5 – 0.94
Mean WBC, (· 109/L (SD) 13.4– 5.2 13.4– 5.1 13.4 – 5.4 13.4 – 5.5 13.5 – 5.7 13.4 – 5.4
Mean C-reactive protein,
mg/dL (SD)
19.8 – 18.3 20.2 – 17.7 19.5 – 18.8 20.2 – 18.7 20.9 – 19.2 19.4 – 18.2
Mean APACHE II score (SD) 6.9 – 5.0 6.9 – 4.7 6.9 – 5.2 7.0 – 5.0 7.1 – 4.8 6.9 – 5.2
Anatomic site of infection, n (%)
Gallbladder and biliary tract 55 ( 5.4) 26 ( 5.1) 29 ( 5.6) 63 ( 5.1) 29 ( 4.8) 34 ( 5.5)
Stomach or duodenum 189 ( 18.5) 91 ( 18.0) 98 (18.9) 228 (18.6) 116 (19.0) 112 (18.1)
Appendix 534 ( 52.1) 269 ( 53.3) 265 (51.1) 621 (50.5) 308 (50.6) 313 (50.5)
Large bowel 166 ( 16.2) 86 ( 17.0) 80 (15.4) 213 (17.3) 107 (17.6) 106 (17.1)
Small bowel 71 ( 6.9) 31 ( 6.1) 40 ( 7.7) 90 ( 7.3) 43 ( 7.1) 47 ( 7.6)
Others 5 ( 0.5) 1 ( 0.2) 4 ( 0.8) 8 ( 0.7) 4 ( 0.7) 4 ( 0.6)
Unknown 4 ( 0.4) 1 ( 0.2) 3 ( 0.6) 6 ( 0.5) 2 ( 0.3) 4 ( 0.6)
Polymicrobial infection, n (%) 629 ( 61.4) 319 ( 63.2) 310 (59.7) 741 (60.3) 381 (62.6) 360 (58.1)
Bacteremia, n (%) 29 ( 2.8) 15 ( 3.0) 14 ( 2.7) 37 ( 3.0) 22 ( 3.6) 15 ( 2.4)
APACHE =Acute Physiology and Chronic Health Evaluation; BMI = body mass index; cIAI= complicated intra-abdominal infections;
ITT = intent-to-treat; PP = per-protocol; SD= standard deviation; WBC=white blood cell count. *Antibiotic administered within the week
preceding the start of study therapy.
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treatment arms (4.3% vs. 3.4% of the moxifloxacin- and
comparator-treated patients, respectively) (Table 6) and were
not attributed to study medication. All of these fatalities were
treatment failures or indeterminate cases (patients in whom
clinical evaluation was not possible to determine) prior to
their deaths, and their infections developed into sepsis or
septic shock and resulted in further complications such as
acute respiratory distress syndrome, hemodynamic shock,
multiple organ dysfunction syndrome, embolism, hemor-
rhage, respiratory or cardiac failure, or pneumonia.
Discussion
The results of these pooled analyses suggest that, for the
treatment of secondary peritonitis, moxifloxacin has similar
clinical and bacteriologic efficacy and a similar safety profile
compared with other antibiotic agents currently approved for
this indication in patients with infections of mild-to-moderate
severity. This comparable efficacy was found across different
sites of infection as well as causative bacteria. From all en-
rolled (N= 2,444) patients with cIAIs in these four random-
ized clinical trials, secondary peritonitis occurred in 1,229
(50%) patients, reflecting the high prevalence of this more
severe disease among patients with mild-to-moderate, com-
munity-acquired cIAI origin.
Broad spectrum antibiotic therapy is an important part of
the management of secondary peritonitis. In accordance with
previous reports [5,24–26] and consistent with a patient
population with community-acquired mild-to-moderately
severe cIAIs, E. coli, B. fragilis and other Bacteroides spp.
Table 2. Clinical Success Rates at TOC (10 to 45 Days Post-Therapy) in Patients
with Secondary Peritonitis in the Pooled Analysis of cIAIs
Study
Moxifloxacin
n/N (%)
Comparators
n/N (%)
95% CI
(%, %)
Point
estimate
(%)
Relative
weight Heterogeneity
PP populations
Malangoni (2000–2003, USA)13 66 /89 (74.2) 57/73 (78.1) - 17.07–9.22 - 3.92 15.74% 0.02 ( 0.58%)
Weiss (2001–2002, Europe)14 92/111 (82.9) 110/135 (81.5) - 8.19–10.99 1.40 23.90% 0.81 (25.25%)
Solomkin (2005–2007, Asia)15 18 /24 (75.0) 28/30 (93.3) - 37.82–1.15 - 18.33 5.23% 2.38 (73.93%)
De Waele (2006–2009, Europe)16 255/281 (90.7) 264/281 (94.0) - 7.59–1.18 - 3.20 55.13% < 0.01 ( 0.24%)
Total 431/505 (85.3) 459/519 (88.4) - 7.06–1.05 - 3.01 Chi2 = 3.21
p value = 0.360*
ITT populations
Malangoni (2000–2003, USA)13 69/129 (53.5) 63/122 (51.6) - 10.51–14.21 1.85 20.46% 0.85 (20.94%)
Weiss (2001–2002, Europe)14 93/127 (73.2) 114/152 (75.0) - 12.10–8.56 - 1.77 22.58% 0.17 ( 4.27%)
Solomkin (2005–2007, Asia)15 18 /26 (69.2) 28 /31 (90.3) - 41.66–- 0.52 - 21.09 4.61% 2.66 (65.61%)
De Waele (2006–2009, Europe)16 269/327 (82.3) 277/315 (87.9) - 11.16–- 0.19 - 5.67 52.35% 0.37 ( 9.18%)
Total 449/609 (73.7) 482/620 (77.7) - 8.54–0.61 - 3.96 Chi2 = 4.06
p value = 0.255*
CI = confidence interval; cIAI= complicated intra-abdominal infections; ITT = intent-to-treat; PP, per-protocol; TOC = test-of-cure.
*P value refers to heterogeneity test and not to comparison of clinical efficacy between treatment groups.
FIG. 1. Forest plots for clinical efficacy in individual studies and overall (PP and ITT populations).
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were the most frequently isolated pathogens. Moxifloxacin
achieved similar bacteriological eradication rates to com-
parator regimens against these (and other causative) bacteria.
The anti-anaerobic activity of moxifloxacin observed in this
subset of patients was similar to that reported in a recent
review by Goldstein et al. [27] on a broader population.
Against susceptible anaerobic pathogens (MIC £ 2 mg/L),
moxifloxacin achieved high bacteriologic eradication and
clinical success rates of 84.5% and 83.1%, respectively [27].
Importantly, the clinical success rate was maintained at more
than 80% beyond the susceptibility breakpoint of 4 mg/L,
and declining to 67.7% only at an MIC of 32mg/L [27].
Antibiotic resistance among bacteria implicated in the
pathogenesis of polymicrobial peritonitis is considered as a
critical issue in empiric therapy, as patients treated with an-
tibiotics to which the pathogens are resistant are more likely
to experience treatment failure and worse outcome [28].
However, as observed in a previous analysis of cIAI patients
[27], the rates of clinical and bacteriological success achieved
with moxifloxacin appear to be maintained well beyond the
susceptibility breakpoint for key pathogenic species; this was
observed during the long interval between 2000 and 2009
including each Phase III study period. Thus, despite recent
warnings about the occurrence of resistant bacteria to major
classes of antibiotics used to treat cIAIs that include not
only fluoroquinolones but also carbapenems and piperacillin-
tazobactam [29–38], our results may support the empiric use
of antibiotics with a spectrum of activity covering the main
causative organisms in cIAI patients with mild-to-moderate
disease.
Pseudomona aeruginosa was isolated as a potential path-
ogen in a small number of patients. Although moxifloxacin
has weak activity against P. aeruginosa, patients from whom
this species was isolated responded well to therapy. This
suggests that P. aeruginosamight have been present either as
a colonizer or as a co-pathogen, which is consistent with the
view that the prevalence of strains tends to be low in com-
munity-acquired IAIs [7].
Enterococci were also isolated in a small number of pa-
tients. Although the use of antibiotic therapy in patients with
cIAIs harboring enterococci has proved controversial, it is
now accepted that for patients with community-acquired in-
fections, coverage against enterococci is not necessary as
these bacteria are found mainly in nosocomial cIAIs and after
previous exposure to antibiotics [3,39].
Fluoroquinolones possess potent in vitro activity against
aerobic gram-negative bacteria; however, ciprofloxacin and
levofloxacin lack anti-anaerobic activity, therefore, they need
to be used in combination with metronidazole to provide
coverage against Bacteroides spp. and other anaerobes [3,4].
Moxifloxacin has the advantage that it is active against both
aerobic and anaerobic bacteria [5,40–41] and can be ad-
ministered once daily as monotherapy [3,4]. As secondary
Table 3. Clinical Success at TOC (10–45 Days
Post-Therapy) by Anatomical Site of Infection
in Patients with Secondary Peritonitis
in the Pooled Analysis of cIAIs (PP Population)
Site of infection
Moxifloxacin
n/N (%)
Comparator
n/N (%)
Gallbladder and
biliary tract
26/ 26 ( 100) 28/ 29 (96.6)
Stomach or
duodenum
79/ 91 ( 86.8) 91/ 98 (92.9)
Appendix 229/269 ( 85.1) 244/265 (92.1)
Large bowel 70/ 86 ( 81.4) 59/ 80 (73.8)
Small bowel 25/ 31 ( 80.6) 32/ 40 (80.0)
Others/Unknown 2/ 2 (100) 5/ 7 (71.4)
cIAI= complicated intra-abdominal infections; PP= per-protocol;
TOC = test-of-cure.
Table 4. Bacteriological Success (Eradication/Pre-
sumed Eradication) Rates at TOC (10–45 D Post-
Therapy) in Patients with Secondary Peritonitis in
the Pooled Analysis of cIAIs (MBV Population)
Bacteria type
Moxifloxacin
n/N (%)
Comparator
n/N (%)
Aerobic only 133/160 (83.1) 162/181 (89.5)
Anaerobic only 8/ 11 (72.7) 6/ 8 (75.0)
Mixed (aerobic
and anaerobic)
186/226 (82.3) 173/204 (84.8)
Overall* 328/398 (82.4) 342/394 (86.8)
MBV =microbiologically valid; TOC = test-of-cure. *One isolate
in each treatment group of other type of organism was successfully
eradicated.
Table 5. Bacteriological Success (Eradication/
Presumed Eradication) Rates by Baseline Pathogen
at TOC (10–45 D Post-Therapy)
(MBV Population)
Organism
Moxifloxacin
n/N (%)
Comparator
n/N (%)
Gram-positive aerobic 155/197 (78.7) 161/195 (82.6)
Enterococcus avium 21/ 25 (84.0) 18/ 23 (78.3)
Enterococcus faecalis 28/ 36 (77.8) 30/ 42 (71.4)
Enterococcus faecium 17/ 23 (73.9) 15/ 20 (75.0)
Streptococcus anginosus 47/ 59 (79.7) 56/ 65 (86.2)
Streptococcus constellatus 42/ 54 (77.8) 42/ 45 (93.3)
Gram-negative aerobic 351/420 (83.6) 335/387 (86.6)
Citrobacter freundii 9/ 11 (81.8) 12/ 13 (92.3)
Enterobacter cloacae 10/ 13 (76.9) 8/ 9 (88.9)
Escherichia coli 227/269 (84.4) 236/270 (87.4)
Klebsiella oxytoca 21/ 24 (87.5) 15/ 18 (83.3)
Klebsiella pneumoniae 27/ 32 (84.4) 25/ 31 (80.6)
Pseudomonas aeruginosa 43/ 52 (82.7) 30/ 36 (83.3)
Proteus mirabilis 14/ 19 (73.7) 9/ 10 (90.0)
Gram-positive anaerobic 22/ 31 (71.0) 33/ 39 (84.6)
Clostridium species 18/ 23 (78.3) 24/ 28 (85.7)
Peptostrepcococcus
species
4/ 8 (50.0) 9/ 11 (81.8)
Gram-negative anaerobic 237/279 (85.0) 222/254 (87.4)
Bacteroides distasonis 16 /18 (88.9) 14/ 16 (87.5)
Bacteroides fragilis 90/107 (84.1) 101/114 (88.6)
Bacteroides ovatus 19/ 24 (79.2) 14/ 15 (93.3)
Bacteroides
thetaiotaomicron
48/ 56 (85.7) 49/ 56 (87.5)
Bacteroides uniformis 16/ 17 (94.1) 19/ 23 (82.6)
Bacteroides vulgatus 17/ 20 (85.0) 7 /9 (77.8)
Other Bacteroides species 31/ 37 (83.8) 18/ 21 (85.7)
MBV =microbiologically valid; TOC = test-of-cure.
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peritonitis is frequently polymicrobial [9], in accordance with
data of the current analysis showing the presence of two or
more pathogens in approximately 60% of patients, a broad-
spectrum, single-agent therapy, such as moxifloxacin, offers
practical advantages over multi-dose combination regimens.
The appendix is the most common source of infection in
community-acquired cIAIs, followed by the colon and
stomach [42]; similar findings were observed in our analysis
showing that these sites accounted for more than 80% of all
peritonitis cases reported across the four studies. Treatment
with moxifloxacin resulted in similar clinical success rates to
comparator regimens in secondary peritonitis originating
from these and other less common anatomic sites. Most pa-
tients in this study had community-acquired cIAIs of mild-to-
moderate severity on the basis of the APACHE II scoring
system. Across the four trials there were relatively few pa-
tients at higher risk of clinical failure such as those with
higher APACHE II scores ( ‡ 15; 7.7%), hospital-acquired
infection (4.0%), renal dysfunction or disorders (4.8%), and
the presence of other risk factors such as diabetes mellitus
(10.4%), older age (20.3%), and previous antibiotic therapy
(34%) were observed in a small proportion of patients. Thus,
the population in this pooled analysis best reflects the mod-
erately ill cIAI patients as described in recent SIS/IDSA
guidelines and our clinical data support the use of moxi-
floxacin in patients with mild-to-moderate cIAIs as re-
commended in these guidelines [3,4].
Pooled safety and tolerability data indicated that moxi-
floxacin was generally well tolerated in cIAI patients with
secondary peritonitis. Although the overall incidence of AEs
was higher in the moxifloxacin treatment arm, the incidence
of study drug-related AEs, serious AEs, and deaths were
similar between treatment groups in the ITT/safety popula-
tion. The most frequent treatment-emergent AEs were
gastrointestinal disorders including diarrhea, nausea, and
vomiting. Clostridium difficile infections may be associated
with moxifloxacin or other FQ treatment [43]. However, in
this pooled dataset C. difficile infection was rare and it was
not reported with higher frequency in MXF-treated patients
than in COMP-treated patients. Surgical infections are not
infrequent complications following open surgery but there
was no clinically meaningful difference in rates of surgical
infections between the two treatment groups in this pooled
analysis. Of note, cardiac adverse events that are included in
the warning labeling of moxifloxacin (such as QT interval
prolongation, [12]) occurred in low frequency ( < 1%) among
patients. Most AEs were not attributable directly to study
medications, which suggests that many were related to the
fact that patients were hospitalized for surgery in addition to
their need for IV antibiotic therapy.
Patients with secondary peritonitis constitute an important
sub-group within the cIAI patient population and for whom
there is an increased risk of mortality from severe sepsis and
septic shock if adequate antibiotic therapy is not administered
promptly. Initiation of surgical source control in addition to
the broad-spectrum antibiotic therapy, as performed in con-
trolled clinical trials and in dedicated hospitals, prevented
multiple organ dysfunction syndrome or sepsis in our patients
which may count for the relatively low mortality rate ( < 5%).
The strength of the data presented here is that the four studies
included a large number of patients with secondary perito-
nitis who had an advanced disease but were not critically ill
and thus representative of the moderately ill cIAI patient
category as described in recent SIS/IDSA guidelines [3,4].
The APACHE II scoring system was used to describe the
severity of the disease in this analysis, as it was in most other
studies in this field. Originally devised as a score to predict
mortality upon ICU admission and generally considered a
good marker of severity in these patients, its value in peri-
tonitis has recently been questioned because it does not take
into account the effect of interventions that may alter phys-
iologic paramaters [8]. Patients with mild-to-moderate cIAIs
generally have APACHE II scores of < 10 that are not as-
sociated with high mortality risk [25,44]. However, this
evaluation is often performed before patients are operated on
and remains stable hemodynamically. The APACHE II score
may not be the most reliable way to assess the severity of
surgical patients and a more specific scoring system—such as
the Mannheim peritonitis index (MPI), which includes the
description of peri-operative findings—may have been a
more appropriate choice [8]. Another weakness of this pooled
analysis was the heterogeneity of follow up periods after the
end of antibiotic therapy. In the study by Solomkin et al., the
TOC visit was carried out within 10–14 d of end-of-therapy,
possibly precluding the identification of late clinical failures,
recurrences or super-infections, resulting in the highest
response rate for the comparator group [15]. Late clinical
failures were captured in the other three larger studies where
patients were monitored for longer periods post-therapy
[13–14,16].
In conclusion, in this pooled analysis it has been observed
that moxifloxacin has similar clinical and bacteriologic effi-
cacy and a good safety profile compared with those of other
previously approved antibiotic regimens in the treatment of
mild-to-moderate secondary peritonitis. Despite certain limi-
tations, the data from this pooled analysis provides support for
Table 6. Incidence of Treatment-Emergent
AEs in Patients with Secondary Peritonitis
(ITT Population)
Moxifloxacin Comparator
(N= 609) (N= 620)
MedDRA PT Event n (%) n (%)
Any AEs 410 (67.3) 371 (59.8)
Nausea 49 ( 8.0) 28 ( 4.5)
Diarrhea 39 ( 6.4) 49 ( 7.9)
Abdominal pain 26 ( 4.3) 19 ( 3.1)
Constipation 21 ( 3.4) 19 ( 3.1)
Surgical site infection 65 (10.7) 51 ( 8.2)
Post-operative
Surgical site infection
10 ( 1.6) 6 ( 1.0)
Drug-related AEs
occurring in > 5 patients
in either treatment
group Any
127 (20.9) 124 (20.0)
Serious AEs 110 (18.1) 88 (14.2)
Drug-related serious AEs 19 ( 3.1) 6 ( 1.0)
Premature discontinuations
due to AEs
31 ( 5.1) 25 ( 4.0)
Deaths 26 ( 4.3) 21 ( 3.4)
AE= adverse event; ITT = intent-to-treat; MedDRA PT=Medical
Dictionary for Regulatory Activities Preferred Term.
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the use of moxifloxacin as a valuable therapeutic option in the
group of patients with advanced cIAIs, which is consistent
with current treatment guidelines [3,4].
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